# A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

> **NCT02799095** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mural Oncology, Inc** · enrollment: 243 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ALKS 4230
- **DRUG:** ALKS 4230 + pembrolizumab

## Key facts

- **NCT ID:** NCT02799095
- **Lead sponsor:** Mural Oncology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-14
- **Primary completion:** 2023-03-27
- **Final completion:** 2023-08-02
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02799095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02799095, "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02799095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*